Explore the vast range of titles available.

BackgroundThe use of therapy with anti-cytokine biologicals in routine practice has significantly increased the percentage of children showing good response to therapy and reduced the time to achieve pharmacological remission. Nevertheless, the problem related to selecting the optimal drug for a certain patient still remains to be solved.ObjectivesThis study was aimed at identifying clinical and laboratory parameters associated with response to tocilizumab (TOC) treatment in patients with RF-negative polyarticular JIA.MethodsThe prospective study to assess TOC efficacy involved 55 patients with RF-negative polyarticular JIA aged 9.42 years (IQR 5.96–13.42), with females (85.5%) predominating was conducted at the National Medical Research Centre of Children’s Health (Moscow). Treatment efficacy was evaluated using the ACRPedi criteria; Wallace’s criteria were used to assess whether a patient had reached inactive disease or remission. The potential baseline characteristics associated with treatment response were identified using univariate and multivariate logistic regression analyses. Baseline factors included the clinical, laboratory, and anamnestic data.ResultsTOC therapy showed high efficacy in children with RF-negative polyarticular JIA: 81.8/67.3/47.3/23.6% of patients reached the ACR30/50/70/90 criteria for the end of follow-up, respectively. The median time of achieving at least 30% improvement from baseline (ACR30) was 1 months (IQR 1:3).Univariate analysis showed that earlier age at initiation of Tocilizumab therapy, higher physician’s global assessment score using the 100-point Visual Analogue Scale, and longer morning stiffness were the factors associated with reaching ACR90. Younger age at therapy initiation, greater number of swollen joints and joints with limited range of motion, and history of using fewer biologicals are the factors associated with reaching inactive disease and remission. However, multifactorial analysis showed that only earlier age at initiation of TOC therapy was a statistically significant factor associated with reaching the best response to therapy in all the models.ConclusionsEarlier initiation of TOC therapy is associated with higher chances for reaching ACR90 and pharmacological remission in patients with RF-negative polyarticular JIA. Further studies in larger cohorts are needed to identify the optimal age at therapy initiation.Disclosure of InterestE. Alexeeva: None declared, T. Dvoryakovskaya Grant/research support from: Roche, Pfizer, M. Soloshenko: None declared, R. Denisova: None declared, K. Isaeva: None declared, A. Mamutova: None declared, V. Gladkikh: None declared, A. Moskalev: None declared

BackgroundDevelopment of biologics gives rise to novel classes of drugs, offering more options for treating children with primary or secondary failure of anti-TNF therapy. However, the question of whether or not previous exposure to biologic therapy and the number of previously administered biologics influence the efficacy of current treatment still needs to be solved.ObjectivesTo compare tocilizumab efficacy in biologics-naïve and biologics-switched patients with JIA.MethodsComparative analysis involved patients who had initiated TOC treatment at the National Medical Research Centre of Children’s Health (Moscow) depending on previous history of biologics therapy. Treatment efficacy was evaluated according to the dynamics of clinical and laboratory signs using the ACRPedi criteria. The Wallace criteria were used to evaluate whether or not remission had been achieved.ResultsThirty-two patients were biologics-naïve and 43 patients switched to TOC were previously treated with ETA (n=10), ADA (n=34), certolizumab (n=2), and infliximab (n=1). Children in the biologics-naïve group differed from the switchers in a number of important baseline parameters: shorter disease duration (2.13 [1.25:5.34] and 7.42 [3:10.75] years, respectively; p<0.001) and lower arthritis severity indices (the number of joints affected, the CHAQ and JADAS scores). Therapy with TOC in children was found very effective. The CHAQ and JADAS disease activity scores, the CRP and ESR laboratory values, morning stiffness duration, and the VAS score (assessed by both patient and physician), and the number of affected joints (swollen or painful joints, joints with the limited range of motion and with active arthritis) significantly decreased after 4 week therapy in all patients (p<0.01). The percentages of biologics-naïve patients and switchers who achieved ACR90 after the first 12 months of therapy were 31.25% and 25.6%, respectively (p=0.613). A smaller percentage of children achieved stable remission: 4.65% of switchers and 6.25% of biologics-naïve patients (p>0.999).ConclusionsTocilizumab therapy is highly efficient both as the first and subsequent biologic agent. Children with history of therapy with at least one biologic agent have lower chances for achieving remission during the first 12 months of therapy. However, this difference is most likely caused by the longer and more severe arthritis course in children allocated to the group of biologics-switched patients compared to biologics-naïve ones. Further matched large-cohort study is needed to identify predictors of response to therapy.Disclosure of InterestE. Alexeeva: None declared, T. Dvoryakovskaya Grant/research support from: Roche, Pfizer, M. Soloshenko: None declared, R. Denisova: None declared, K. Isaeva: None declared, A. Mamutova: None declared, V. Gladkikh: None declared, A. Moskalev: None declared

BackgroundJuvenile idiopathic arthritis (JIA) is one of the most frequent and most disabling rheumatic diseases in children. Children with JIA receiving immunosuppressive and genetically engineered biologic drugs belong to the high-risk group for the development of bacterial and viral infections, including those administered by preventive vaccines.ObjectivesOur aim was to evaluate the tolerability of the pneumococcal 13-valent conjugate vaccine (PCV) in children with JIA.MethodsIn a prospective cohort study, 3 groups were formed: children with JIA in the remission phase on methotrexate or etanercept (group I), with JIA in the active phase prior to the appointment of methotrexate or etanercept (group II), control group (conditionally healthy children). 0.5 ml of the 13-valent PCV was administered once subcutaneously during therapy in patients in the remission phase or 3 weeks before the appointment of methotrexate or etanercept in patients in the active phase.ResultsAt this stage of work, the tolerability of the 13 PCV vaccine was evaluated in patients with JIA, without systemic manifestations. In our study, the post-vaccination period was asymptomatic in 58% of the children in Group I, 66% in children in Group II, and in 60% in the control group. Most often in the postvaccinal period, local reactions were noted, which were painful at the place of administration of the vaccine in 6% of the children in group I, 8% in group II, and 24% in the control group, respectively. Less developed oedema and hyperemia at the injection site – in 12% of children in group I, 6% in group II, in 8% of children in the control group. There was no significant difference in the incidence of local reactions to vaccination of 13 PKV in patients with JIA and in children of the control group. Analysis of the time of occurrence and duration of local and systemic reactions to vaccination of 13 PKV showed that the maximum severity of symptoms was noted in the first day, by the 2–3 day of observation, complaints and fever disappeared. The increase in local reactions was noted 2 days after immunisation, followed by extinction to 3–4 days of follow-up. There were no serious adverse events in the post-vaccination period.ConclusionsVaccination with the 13-valent PCV in children with JIA is safety and is not accompanied by the development of serious adverse events.Disclosure of InterestE. Alexeeva Grant/research support from: Roche, Pfizer, Centocor, Novartis, T. Dvoryakovskaya Grant/research support from: Roche, Pfizer, M. Soloshenko: None declared, R. Denisova: None declared, K. Isaeva: None declared, A. Mamutova: None declared, N. Mayansky: None declared, N. Tkachenko: None declared, I. Zubkova: None declared, T. Kaluzhnaya: None declared, A. Gayvoronskaya: None declared, M. Broeva: None declared, M. Fedoseenko: None declared

The author proposes original tools for improving formulas of the maximum likelihood estimation method for logistic regression, the weight of evidence formula including the information value indicator formula, and the Gini index with a view to providing the use of a continuous target variable assuming probabilistic values. The approach to the pursuance of this research consists of the application of continuous weight functions meeting certain conditions to evaluate a generalized logarithm of the likelihood function including its generalized gradient vector and generalized Hessian matrix and also the application of probability theory to generalize weight of evidence and the Gini index.

BackgroundThe main clinical manifestations of monogenic autoinflammatory syndromes and polygenic Systemic juvenile idiopathic arthritis (sJIA) are similar and presented with fever, migratory erythematous rash, arthritis/arthralgia and eye manifestations. The right diagnosis is reached using gene analysis and prognosis depends on correct personified therapy.ObjectivesTo evaluate frequency of CAPS and TRAPS in Russian systemic JIA pts.Methods170 pts (61 boys, 109 girls) at the age from 1 to 17y. (6.9 (3.9;9.4) followed with a diagnosis of sJIA were selected according to the clinical manifestations, with subsequent obligatory genetic counseling in the Department of Rheumatology of the Scientific Center for Children's Health. The median age of disease onset was 2.9 (1.2;6.0)y., disease duration – 4.0 (2.6;5.4)y. The commonest features were fever (100%), arthritis/arthragia (100%), rash (163 pts/96%), hepato- and splenomegaly (160/94%), lymphadenopathy (136/80%), headache (88/52%), abdominal pain (98/58%) and eye manifestations (42/25%). Patients' DNA was sequenced in all coding exons and intronic flanks of the TNFRSF1A and NLRP3 genes.ResultsIn 18/130 (10.6%) pts genetic autoinflammatory syndrome was established. In 12 pts we found mutations in TNFRSF1A: In 9/12 pts - the most frequent mutations c.362G>A (p.R92Q) located in exon 4 and associated with the mild progression of TRAPS. One pt revealed a TNFRSF1A mutation c.374G>A (C96Y). Two pts identified mutations which were not previously described in the databases. They had TNFRSF1A deletion c.337_339del (p.Glu113del) and frameshift mutation c.792delT (p.Lys265Serfs*87) located in exons 04 and 09 of TNFRSF1A gene, respectively. The median age of disease onset was 5.3 y. Pts had a median 85 symptomatic days per year, attacks were recurrent in 78%. A family history was present in 3 pts: 2 girls with R92Q and one – with C96Y mutation.Four pts identified mutations in NLRP3 gene. One pt had mutation c.598G>A (p.Val200Met). Three pts had mutations which were not previously described in the databases. One pt had a mutation c.796C>T (p.Leu266Phe) in exon 04 of NLRP3 gene. Two other pts had mutations c.2861C>T and c.2173C>A, respectively. Pts with c.2173C>A and c.796C>T mutations have CINCA/NOMID phenotype and dramatic effect of canacinumab.2 pts presented changes in both genes. They had R92Q mutation in TNFRSF1A and polymorphism Q705K in NLRP3 gene.In 15 (7.6%) pts we identified NLRP3 gene polymorphism Q705K associated with elevated levels of IL1.ConclusionsOur results suggests for a relatively frequent incidence of CAPS and TRAPS in Russian systemic JIA pts. The number of genetically confirmed pts with periodic fever syndromes in Russia is very low. It is important to establish a network for genetic testing of periodic fever syndromes.Disclosure of InterestE. Alexeeva Grant/research support from: Roche, Novartis, UCB, K. Savostyanov Grant/research support from: Novartis, T. Sleptsova Grant/research support from: Novartis, UCB, A. Pushkov Grant/research support from: Novartis, T. Bzarova Grant/research support from: Pfizer, S. Valieva Grant/research support from: Roche, R. Denisova Grant/research support from: Roche, Novartis, Pfizer, UCB, K. Isayeva Grant/research support from: Roche, Novartis, E. Chistyakova: None declared, O. Lomakina: None declared, M. Soloshenko: None declared, E. Kaschenko: None declared

BackgroundPatients with polyarticular-course Juvenile idiopathic arthritis (pcJIA) have risk for profound disability.Although these patients may respond to methotrexate (MTX) or biological agents approved for pcJIA, up to 30% continue to have active disease.Interleukin-6 (IL-6) is concentrations are positively correlated with the severity of joint involvement and with C-reactive protein (CRP) levels. Tocilizumab is effective drug for the treatment of JIA refractory to immunosuppressive drugs.ObjectivesTo evaluate safety and efficacy of tocilizumab treatment in children with pcJIAMethodsAnalysis of efficacy and safety tocilizumab therapy was performed in 46 patients (4 - RF+, 3-enthesitis related arthritis, 1-psoriatic JIA) and in 24 patients, whom follow up period was 6 and 12 m. Median age was 9,8 y (range; 1,9 to 17,2 y) and median disease duration was 5,1y (range; 0.4 to 13,7 y). Tocilizumab was administrated intravenously at a dose of 8or 10 mg/kg every 4 weeks. 29 patients were treated by biologics previously. The majority of patients received concomitantDMARDs, 31 patients received methotrexate, 1-leflunomid, 1-sulfasalazin,5-cyclosporin and 8- prednisolone at dose 0.4 (0.2; 1) mg/kg/day. 14 patients had uveitis: 6-not active,1-subactive and 7-active. Efficacy end points included the American College of Rheumatology (ACR)for improvement 30 (ACR30), ACR50, ACR70, ACR90 and criteria of inactive disease andindex JADAS10. During the follow-up period, significant side-effects were sought.ResultsThe ACR Pedi 30, 50, 70, 90 and 100 improvement were achieved by 92% (n=36), 82% (n=32), 56% (n=22), 23% (n=9),and 12% (n=5) of patients at Week 24 (n=39), by 100% (n=24), 87% (n=21), 83% (n=20), 54% (n=13), and 20% (n=5) of patients at Week 48 (n=24)respectively. Inactive disease was achieved by 14/39 (36%) of patients at week 24 and by 12/24 (50%) of patients at week 48. The JADAS10 decreased from 23,4 (14,8; 27,8) to 6,2 (1,6; 11,8) at week 24 (p<0.001) and to 2,0 (0,5; 4,9) at week 48 (p<0.001). The number of platelets decreased from 383 x109/l (302; 488) to 250 (220; 282) at week 24 (p<0.001) and to 258 (216; 284) at week 48 (p<0.001), number of leucocytes – from 8,8 x109/l (7,6; 9,9) to 6,5 (5,3; 7,3) at week 24 (p<0.001) and to 6,4 (4,7; 6,8)) at week 48 (p<0.001); level of hemoglobin increased from 112 (100; 123) g/l to 126 (118; 132) at week 24 (p<0.01) and to 129 (122; 136)) at week 48 (p<0.001).The frequently observed non-severe adverse events were nasopharyngitis, upper respiratory tract infections and gastroenteritis. No cases of opportunistic infections, malignancies or death were reported. 12 patients had incidences of neutropenia, 2 – thrombocytopenia,7-increased level of ALT and AST. Tocilizumab treatment was discontinued in 7 patients during the follow-up 48 weeks period. The causes for cancellation were lack of efficacy (n=6), infusion reaction (n=1), flare (n=1). 5patients were switched to antiTNF blockers and 2 – to abatacept.ConclusionsTocilizumab treatment provided clinically meaningful improvement for patients with pcJIA. Tocilizumab induced remission of the disease The safety profile of tocilizumab was consistent that seen in other studiesDisclosure of InterestE. Alexeeva Grant/research support from: Roche, Novartis, UCB, R. Denisova Grant/research support from: Roche, Novartis, Pfizer, UCB, S. Valieva Grant/research support from: Roche, T. Bzarova Grant/research support from: Pfizer, K. Isayeva Grant/research support from: Roche, Novartis, T. Sleptsova Grant/research support from: Novartis, UCB, E. Chistyakova: None declared, A. Chomahidze: None declared, O. Lomakina: None declared, M. Soloshenko: None declared, A. Fetisova: None declared, E. Kashchenko: None declared

BackgroundTNFα is one of the most important cytokine in the pathogeneses of poly-JIA. There are several TNF inhibitors for the treatment poly-JIA. Switching TNF-blockers is often strategy in the treatment of poly-JIA.MethodsAn open observational study in patients with poly-JIA taking the second TNFinhibitor. A total of 119 patients (46 boys and 73 girls) were included in this study. The mean age was 11 (7;14), disease duration was 5 (3;8) years. By the switching time 54/119 had active polyarthritis, 58/119 – olygoarthritis, 7/119 – active uveitis without arthritis. Infliximab was the first TNF inhibitor in 105/119, adalimumab – in 3/119, etanercept – 11/119. 81/119 were switched to adalimumab, 38/119 – to etanercept. Analysis of survival the second TNF blocker treatment was performed in all patients by Kaplan–Meier curve.ResultsThe causes for cancellation of the first and second TNF blockers were second inefficacy (3,7% and 8%), adverse events (5,6% and 2,5%) and administration causes (7% and 8%). Infliximab was cancelled because of primary inefficacy (7/105, 6.7%), second inefficacy (57/105, 54.3%), adverse events (12/105, 11.4%), relapse of uveitis (7/105, 6.7%), disease remission (19/105, 18.1%), administration causes (3/105, 2.8%). Etanercept was discontinued because of primary inefficacy (1/11, 9%), second inefficacy (2/11, 18%), adverse events (2/11, 18%), relapse of uveitis (6/11, 55%). Adalimumab was cancelled because of primary inefficacy (1/3), adverse events (1/3), administration causes (1/3). The second TNF inhibitor treatment survival in patients with the primary inefficacy of the first TNF inhibitor at 1,2 year was 73%, at 1,8 year was 73%, at 2,4 year was 53%. The second TNF inhibitor treatment survival in patients with the second inefficacy of the first TNF inhibitor at 1,2 year was 82%, at 1,8 year was 82%, at 2,4 year was 69%. The second TNF inhibitor treatment survival in patients with the remission of the first TNF inhibitor and relapse of disease at 1,2 year was 82%, at 1,8 year was 82%, at 2,4 year was 72%. The number of AE was 32.2 and 24.5 per 100 p.y. on the 1st and 2nd TNF blocker treatment, accordingly (p<0,0001).ConclusionsThe highest percent of survival of the second TNF inhibitor treatment was registered in patients with poly-JIA whom the first TNF inhibitor was cancelled because of disease remission and the lowest percent – in patients with poly-JIA whom the first TNF inhibitor was cancelled because of the primary inefficacy of the first TNF inhibitor.Disclosure of InterestT. Bzarova Grant/research support from: Pfizer, E. Alexeeva Grant/research support from: Roche, Novartis, UCB, S. Valieva Grant/research support from: Roche, R. Denisova Grant/research support from: Roche, Novartis, UCB, K. Isayeva Grant/research support from: Roche, Novartis, T. Sleptsova Grant/research support from: Novartis, UCB, E. Chistyakova: None declared, A. Chomahidze: None declared, O. Lomakina: None declared, M. Soloshenko: None declared, A. Fetisova: None declared, E. Kashchenko: None declared

BackgroundJuvenile idiopathic arthritis (JIA) is a chronic arthritis of unknown cause with an onset before 16 years of patient age.Patients with polyarticular-course JIA (pcJIA) have risk for profound disability. Although these patients may respond to methotrexate (MTX) or biological agents approved for pcJIA, up to 30% continue to have active disease.Interleukin-6 (IL-6) is increased in the serum and synovial fluid of patients with pcJIA; IL-6 concentrations are positively correlated with the severity of joint involvement and with C-reactive protein (CRP) levels. Tocilizumab is effective drug for the treatment of rheumatoid arthritis and systemic JIA refractory to immunosuppressive drugs.ObjectivesTo evaluate safety and efficacy of tocilizumab treatment in children with pcJIA.MethodsAnalysis of efficacy and safety tocilizumab therapy was performed in 22 patients (3 - RF+, 3-enthesitis related arthritis), whom follow up period was 6 months (n=21, tocilizumab treatment was discontinued in in 1 patient at week 3). Median age was 9,9 years (range; 2,9 to 17,2 years) and median disease duration was 3,9 years (range; 0.4 to 11,3 years). Tocilizumab was administrated intravenously at a dose of 8 or 10 mg/kg every 4 weeks. 11 patients were treated by biologics previously. The majority of patients received concomitant DMARDs, 18 patients received methotrexate, 1-leflunomid, 1-sulfasalazin, 4- prednisolone at dose 0.5 (0.5; 1) mg/kg/day. 3 patients had uveitis: 2-not active and 1-active. Efficacy end points included the American College of Rheumatology (ACR) Pediatric criteria for improvement 30 (ACR30), ACR50, ACR70, ACR90 and criteria of inactive disease and index JADAS10. During the follow-up period, significant side-effects were sought.ResultsThe ACR Pedi 30, 50, 70, 90 and 100 improvement were achieved by 100% (n=21), 85% (n=18), 52% (n=11), 24% (n=5), and 14% (n=3) of patients at Week 24 (n=21), respectively. Inactive disease was achieved by 7/21 (33%) of patients at week 24. The JADAS10 decreased from 26,5 (19,8; 28,8) to 6,2 (1,4; 18,9) at week 24 (p<0.001). The number of platelets decreased from 432x109/l (348; 505) to 253 (214; 281) at week 24 (p<0.001), number of leucocytes – from 9,0 x109/l (7,8; 9,0) to 6,3 (4,7; 7,1) at week 24 (p<0.01); level of hemoglobin increased from 105 (97; 120) g/l to 127 (120; 132) at week 24 (p<0.01).The frequently observed non-severe adverse events were nasopharyngitis, upper respiratory tract infections and gastroenteritis. No cases of opportunistic infections, malignancies or death were reported. 2 patients had incidences of neutropenia, 1 – trombocytopenia. Tocilizumab treatment was discontinued in 4 patients during the follow-up 24 weeks period. The causes for cancellation were lack of efficacy (n=3) at week 24, infusion reaction (n=1) at week 12. 3 patients were switched to antiTNF blockers and 1 – to abatacept.ConclusionsTocilizumab treatment provided clinically meaningful improvement for patients with pcJIA. Tocilizumab induced remission of arthritis and normalized laboratory parameters of the disease activity The safety profile of tocilizumab was consistent that seen in other studies.Disclosure of InterestNone declared

BackgroundProlonged therapy with biological agents (BAs) may cause adverse events, which leads to the necessity of discontinuation of BAs in patients with juvenile idiopathic arthritis (JIA), once complete disease quiescence has been achieved.ObjectivesTo estimate the length of time in clinical remission and time to disease flare after discontinuation of treatment with BAs.Methods83 patients with JIA (33 – with systemic onset, 50 – with oligo- or polyarticular arthritis) were included in the survey. The cohort was 34,9% (29 patients) male and 65,1% (54 patients) female with a mean age of 11±3,69 years (range 5–17 years). All patients with systemic JIA (sJIA) were treated with tocilizumab, 35 (70%) patients with other types of JIA received etanercept, 15 (30%) – adalimumab. 14 (42,4%) patients with sJIA additionally got methotrexate, 5 (15,1%) – cyclosporine, 5 (15,1%) – glucocorticoids, 1 (3,0%) – leflunomide; 9 (25,7%) and 7 (46,6%) patients took combination therapy of etanercept or adalimumab and methotrexate. Patients were randomized into 2 main groups using envelope method: in a first group a BA was discontinued abruptly, while in the second it was tapered gradually by increasing injection/infusion interval.ResultsDuration of inactive disease/clinical remission during tocilizumab treatment was 43±12,16/37±12,16 months, etanercept – 40±13,13/34±13,17 months, adalimumab – 48±11,9/40±12,06 months. Tocilizumab, etanercept, adalimumab were discontinued in 22 (66,6%), 28 (80,0%), 11 (73,3%) patients and were tapered by increasing injection/infusion interval in 11 (33,4%), 7 (20,0%), 4 (26,7%) cases, respectively. After withdrawal of tocilizumab, etanercept and adalimumab 29 (87,9%), 24 (68,6%), 6 (40,0%) patients remained in remission of JIA for 6±10,23 (1–48) months, 6±5,07 (1–20) months and 6±13,33 (4–38) months, respectively. 4 (12,1%), 11 (31,4%), 9 (60,0%) patients flared within 8±5,65 (6–18) months, 5,5±3,49 (1,5–12) months and 4±4,64 (1–13) months after discontinuation of tocilizumab, etanercept and adalimumab, respectively.ConclusionsWithdrawal of BAs after clinical remission for more than 1,5 years was not associated with a disease exacerbation in more than 70% of patients with JIA. A mean duration of clinical remission after withdrawal of BAs was 6 months.Disclosure of InterestE. Kashchenko Grant/research support from: Novartis, E. Alexeeva Grant/research support from: Roche, Abbott, Pfizer, Bristol-Myers Squibb, Centocor, Novartis, Speakers bureau: Roche, Merck Sharp & Dohme, Abbott, Bristol-Myers Squibb, Medac, Novartis, Pfizer, T. Bzarova Grant/research support from: Roche, Pfizer, Novartis, Speakers bureau: Roche, Merck Sharp & Dohme, Abbott, Pfizer, S. Valieva Grant/research support from: Roche, Bristol-Myers Squibb, Speakers bureau: Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Medac, Novartis, K. Isaeva Grant/research support from: Roche, Novartis, R. Denisova Grant/research support from: Roche, Centocor, Novartis, Speakers bureau: Roche, Merck Sharp & Dohme, Abbott, Medac, O. Lomakina: None declared, T. Sleptsova Grant/research support from: Centocor, Speakers bureau: Merck Sharp & Dohme, Bristol-Myers Squibb, M. Soloshenko: None declared, A. Karaseva: None declared

BackgroundAnti-TNF biologics are highly effective and widely used in clinical practice for the treatment of JIA. However, some children lack of response with few reliable predictors of a good or poor response to treatment found [1–3]. As clinical picture patterns are significantly differ for 7 JIA subclasses, we propose to found predictors of response to therapy for each of JIA category.ObjectivesTo identify clinical and laboratory parameters associated with response to etanercept treatment in 12 months in patients with different JIA category.MethodsPatients from four JIA categories (n=195) were divided to groups with excellent, intermediate and poor response after 12 month treatment with etanercept according to ACRPedi criteria, achieving inactive disease by Wallace criteria and JADAS-71 cut-off point. For each of JIA category univariate and multivariate logistic regression analysis was conducted to identify potential baseline factors associated with treatment response. Baseline factors included clinical, laboratory and anamnestic data.ResultsFrom total cohort 91/90/85/68.5 percent of patients achieved ACR30/50/70/90 in one year etanercept treatment; 45.5% patients were considered excellent responders, 30% - intermediate responders, and 24.5% - poor responders. Highest efficacy of therapy was shown in persistent oligoarthritis patient, lowest – in enthesitis-related arthritis and polyarthritis patients. Potential baseline predictors of excellent and poor response which were significant are described in the table.JIA categoryPredictors of excellent responsePredictors of poor response Persistent oligoarthritissmaller amount of DMARD–Extended oligoarthritisshorter disease duration (DD)–Enthesitis-related arthritis–– longer DDRF-negative polyarthritis– smaller number of joints with limited range of motion (LOM)– longer DD– lower CRP level at the baseline– older ADO– younger age at disease onset (ADO)Analysis showed that poor response in all JIA categories was mainly associated with demographic data (longer DD and older ADO). However, factors associated with excellent response significantly differed depending on JIA category (anamnestic factors, number of involved joints, laboratory factors, and demographic factors).ConclusionsResponse to etanercept therapy is strongly associated with JIA category. Shorter disease duration and lower number of DMARDs used before start of etanercept, lower number of joints with LOM, and lower C-reactive protein at baseline are predictors of better response to etanercept.References Otten MH, et al. JAMA 2011;306:2340–7.Kearsley-Fleet L, et al. Rheumatology (Oxford) 2016;55:840–7.Solari N, et al. J Rheumatol 2013;40:192–200. Disclosure of InterestE. Kashchenko Grant/research support from: Novartis, E. Alexeeva Grant/research support from: Roche, Abbott, Pfizer, Bristol-Myers Squibb, Centocor, Novartis, Speakers bureau: Roche, Merck Sharp & Dohme, Abbott, Bristol-Myers Squibb, Medac, Novartis, Pfizer, T. Bzarova Grant/research support from: Roche, Pfizer, Novartis, Speakers bureau: Roche, Merck Sharp & Dohme, Abbott, Pfizer, S. Valieva Grant/research support from: Roche, Bristol-Myers Squibb, Speakers bureau: Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Medac, Novartis, R. Denisova Grant/research support from: Roche, Centocor, Novartis, Speakers bureau: Roche, Merck Sharp & Dohme, Abbott, Medac, O. Lomakina: None declared, K. Isaeva Grant/research support from: Roche, Novartis, M. Soloshenko: None declared, A. Karaseva: None declared